Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.

Crawford Y, Ferrara N.

Trends Pharmacol Sci. 2009 Dec;30(12):624-30. doi: 10.1016/j.tips.2009.09.004. Review.

PMID:
19836845
2.

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Ebos JM, Lee CR, Kerbel RS.

Clin Cancer Res. 2009 Aug 15;15(16):5020-5. doi: 10.1158/1078-0432.CCR-09-0095. Epub 2009 Aug 11. Review.

3.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

4.

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA.

Science. 2009 Jun 12;324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21.

5.

Phase II trials in journal of clinical oncology.

Cannistra SA.

J Clin Oncol. 2009 Jul 1;27(19):3073-6. doi: 10.1200/JCO.2009.23.1811. Epub 2009 May 18. No abstract available.

6.

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ.

J Clin Oncol. 2009 May 1;27(13):2231-7. doi: 10.1200/JCO.2008.20.0238. Epub 2009 Mar 23.

7.

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS.

Cancer Cell. 2008 Sep 9;14(3):263-73. doi: 10.1016/j.ccr.2008.08.001.

8.

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE.

N Engl J Med. 2007 Dec 27;357(26):2666-76.

9.

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.

Fukumura D, Jain RK.

Microvasc Res. 2007 Sep-Nov;74(2-3):72-84. Epub 2007 May 18. Review.

10.

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group.

J Clin Oncol. 2007 Jun 1;25(16):2212-7.

11.

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23.

12.

Importance of performance status for treatment outcome in advanced pancreatic cancer.

Boeck S, Hinke A, Wilkowski R, Heinemann V.

World J Gastroenterol. 2007 Jan 14;13(2):224-7. Review.

13.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH.

N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.

14.

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM.

J Clin Oncol. 2006 Sep 20;24(27):4441-7.

15.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

16.

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE.

J Clin Oncol. 2005 Nov 1;23(31):8033-40.

17.

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL.

Ann Oncol. 2005 Oct;16(10):1639-45. Epub 2005 Aug 8. Erratum in: Ann Oncol. 2006 Mar;17(3):535.

18.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD.

J Clin Oncol. 2005 May 20;23(15):3509-16.

19.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS.

J Clin Oncol. 2005 Feb 1;23(4):792-9.

20.

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL.

J Clin Oncol. 2004 Sep 15;22(18):3776-83.

Items per page

Supplemental Content

Write to the Help Desk